PepDiana
Back to Evidence
Primary experimental recordPositive observation

PMC9143221::ACT053006

DFTavP1

Evidence text

Paper-level observation

Section 2.3: DFTavP1, in the 4 h postinfection treatment study, showed a major decrease of 54% inhibition at 5 µM.
textConfidence: medium

Assay observation

Activity
Antiviral
Subtype
General Antiviral
Measure
percent_inhibition
Comparator
=
Raw observation
major decrease of 54% inhibition
Normalized measurement
=54%
Value minimum
Not reported by source
Value maximum
Not reported by source
Target
Vero
Assay method
Not reported by source
Sequence
RWLRGLLSGLLRRLLSGLLL
Standardization
ready simple

Source publication

Improved Database Filtering Technology Enables More Efficient Ab Initio Design of Potent Peptides against Ebola Viruses

Pharmaceuticals · 2022

DOI 10.3390/ph15050521 PMC9143221
Parent mention

Related peptide identities

PEPDIA-PLP-002612

Release PepDiana-V1-20260620. The stable record URL can be cited directly in supplementary material and downstream analyses.